Редактирование: MENT

MENT precursor (Methylated in normal thymocytes protein) [C1orf56] [UNQ547/PRO1104]

==Publications==

{{medline-entry
|title=Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/15784189
|abstract=This study reports the preclinical evaluation of the bone and muscle protective potential of the synthetic androgen 7alpha-methyl-19-nortestosterone ([[MENT]]trade mark), as assessed in the aged orchidectomized rat model. Aged (13-month-old) orchidectomized Wistar rats were treated with different doses of [[MENT]] (4, 12 or 36 microg/day) subcutaneously for 16 weeks via mini-osmotic pumps. Analysis of the effects of androgen deficiency versus [[MENT]] replacement was performed using quantitative computed tomography (pQCT), dual energy X-ray absorptiometry (DEXA) and biochemical markers of bone turnover. At the end of the study period, prostate weight in orchidectomized rats treated with low- (4 microg/day) or mid-dose (12 mug/day) [[MENT]] remained significantly lower compared to the sham-operated animals (-47% and -25%, respectively). High-dose [[MENT]] (36 microg/day), on the other hand, induced prostate hypertrophy ( 21% versus sham). Low-, mid- and high-dose [[MENT]] were found to be effective in suppressing the acceleration of bone remodeling following orchidectomy, as assessed by osteocalcin and deoxypyridinoline. In addition, low-, mid- and high-dose were able to prevent the orchidectomy-induced bone loss, as evaluated by DEXA at the femur and total-body and by pQCT at the femur. Compared to sham-operated animals, the low- and mid-dose [[MENT]] groups showed no decline in lean body mass and no muscle atrophy (as measured by m. quadriceps weight) at 16 weeks, whereas high-dose [[MENT]] was associated with a significant decline in lean body mass (-8.5% versus sham) and quadriceps weight (-10.6%). We conclude that, in the aged orchidectomized rat model, low- and mid-doses of the synthetic androgen [[MENT]] have bone and muscle protective effects and do not induce prostate hypertrophy. The bone protective action of high-dose [[MENT]], however, occurs at the expense of muscle wasting and prostate hypertrophy. Our findings support the need for human studies to explore the potential of [[MENT]] as an option for androgen replacement in aging men.
|mesh-terms=* Absorptiometry, Photon
* Aging
* Animals
* Body Composition
* Bone and Bones
* Estrenes
* Male
* Models, Animal
* Muscle, Skeletal
* Muscular Atrophy
* Orchiectomy
* Rats
* Rats, Wistar
* Tomography, X-Ray Computed

|full-text-url=https://sci-hub.do/10.1016/j.bone.2005.01.003
}}